What is the mechanism of action and therapeutic effect of tepotinib?

Tepotinib is a targeted therapy drug mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying MET gene mutations. Its mechanism of action and therapeutic effects make it important in cancer treatment. As a MET inhibitor, Tepotinib can prevent the proliferation and growth of tumor cells by targeting the MET signaling pathway, especially those cancer cells with MET gene amplification or MET gene mutation.

The mechanism of action of Tepotinib mainly relies on its inhibitory effect on MET receptor tyrosine kinase. METThe receptor is a transmembrane receptor kinase that usually plays an important role in cell growth, migration and survival. When the MET gene is mutated or amplified, the MET signaling pathway is abnormally activated, promoting the malignant growth of tumor cells. Tepotinib inhibits the proliferation and spread of tumor cells by binding to the MET receptor, inhibiting its kinase activity and preventing downstream signaling. This mechanism allows tepotinib to demonstrate significant efficacy in the treatment of tumors driven by MET gene abnormalities.

Tepotinib is mainly suitable for the treatment of patients with non-small cell lung cancer (NSCLC) carrying MET gene mutations or amplifications, especially Tepotinib can be used as a second-line or third-line treatment option for patients with common mutations such as EGFR mutations and ALK rearrangements. Clinical studies have shown that tepotinib can significantly improve progression-free survival (PFS) and overall survival (OS) in these patients. In some advanced or metastatic patients, tepotinib has shown good efficacy and can effectively delay tumor progression and improve patients' quality of life.

Although tepotinib has shown good therapeutic effects, like all targeted therapies, it is also associated with certain side effects. Common side effects include rash, fatigue, abnormal liver function, and gastrointestinal discomfort (such as nausea, vomiting, diarrhea, etc.). These side effects are usually more common in patients early in treatment, but most patients can be relieved by adjusting the drug dose or using symptomatic treatment. In addition, a small number of patients may develop more serious side effects, such as liver toxicity and respiratory problems, which require close monitoring during treatment.

Reference materials:https://www.tepotinib.com/